Andrei Goga is a renowned scientist and medical oncologist who has made significant contributions to the field of cancer research. He received his Bachelor's degree in Cell and Molecular Biology from the University of California, Los Angeles in 1990, followed by an MD and Ph.D in Medicine and Molecular Biology from the same university in 1997. Dr. Goga underwent residency training in internal medicine and fellowship in medical oncology at the University of California, San Francisco from 1997 to 2003. During his PhD and post-doctoral research, he received scientific training in the laboratories of Dr. Owen Witte, Dr. David Morgan, and Dr. J. Michael Bishop, where he studied various aspects of BCR-ABL oncogene signaling pathways and cell cycle deregulation in MYC-driven cancers.
Since 2007, Dr. Goga has been leading an independent lab at the University of California, San Francisco, where he is both a practicing medical oncologist and a basic investigator. Goga lab's primary research goal is to develop new cancer therapies by targeting oncogene signaling pathways for cancer therapy. Through the use of various model systems, Goga lab seeks to understand how oncogenes reprogram the cell cycle, small RNAs, and metabolism to drive tumorigenesis and metastasis. Andrei's lab also focuses on identifying novel tumor vulnerabilities and developing anti-cancer therapeutics based on this knowledge.
Dr. Goga current serves as a Co-Leader of the UCSF Breast Oncology Program of the UCSF Comprehensive Cancer Center. He is also serves as Vice-Chair of the UCSF Department of Cell and Tissue Biology. Overall, Andrei's expertise and research continues to pave the way for the development of effective and innovative cancer therapies.
Awards and Achievements
Andrei Goga is a distinguished scholar who has received awards from various organizations for his research, including the Susan G. Komen Foundation, the Leukemia Lymphoma Society, and CDMRP Breast Cancer Research Program – Era of Hope award. In the past, he has also received funding from the Program in Breakthrough Biological Research (PBBR), V-Foundation, Leukemia, Lymphoma Society (LLS), and Gallo Family Foundation, and ACS Pilot for his research.
Currently, Andrei Goga's research is supported by various organizations, including the NIH/NCI, Atwater Foundation, Breast Cancer Research Foundation, Gazarian Family Foundation, and CDMRP BCRP.
Selected Publications:
Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G, Nomura DK, Goga A. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med. 2016 Apr; 22(4):427-32. PMID: 26950360.
Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, Zhou A, Eyob H, Balakrishnan S, Wang CY, Yaswen P, Goga A*, Werb Z*. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 2015 Oct 1; 526(7571):131-5. PMID: 26416748. *Co-Corresponding
Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, Corella AN, Eyob H, Kessenbrock K, Lawson DA, Marsh LA, Anderton BN, Rohrberg J, Kunder R, Bazarov AV, Yaswen P, McManus MT, Rugo HS, Werb Z, Goga A. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nat Med. 2016 Nov; 22(11):1321-1329. PMID: 27775705.
Rohrberg J, Van de Mark D, Amouzgar M, Lee JV, Taileb M, Corella A, Kilinc S, Williams J, Jokisch ML, Camarda R, Balakrishnan S, Shankar R, Zhou A, Chang AN, Chen B, Rugo HS, Dumont S, Goga A. MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities. Cell Rep. 2020 Mar 10;30(10):3368-3382.e7.
Kilinc S, Paisner R, Camarda R, Gupta S, Momcilovic O, Kohnz RA, Avsaroglu B, L'Etoile ND, Perera RM, Nomura DK, Goga A. Oncogene Regulated Release of Extracellular Vesicles. Dev Cell. 2021 Jul 12;56(13):1989-2006.e6. PMID: 34118203
Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Esserman LJ, van 't Veer LJ, Rugo HS, Curtis C, Klefström J, Matloubian M, Goga A. Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. Nat Commun. 2022 Jun 27; 13(1):3671. PMID: 35760778.
Navickas A, Asgharian H, Winkler J, Fish L, Garcia K, Markett D, Dodel M, Culbertson B, Miglani S, Joshi T, Yin K, Nguyen P, Zhang S, Stevers N, Hwang HW, Mardakheh F, Goga A, Goodarzi H. An mRNA processing pathway suppresses metastasis by governing translational control from the nucleus. Nat Cell Biol. 2023 May 8. doi: 10.1038/s41556-023-01141-9. Epub ahead of print. PMID: 37156909.
Coming Soon - Manuscripts available at bioRxiv:
Camarda, R., Williams, J. B., Malkov, S., Zimmerman, L. J., Manning, S., Aran, D., Beardsley, A., Van De Mark, D., Chen, Y., Berdan, C. A., Louie, S. M., Mahieu, C., Winkler, J., Willey, E., Gagnon, J. H., Shinoda, K., Ansel, K. M., Werb, Z., Nomura, D. K., . . . Goga, A. (2018). Tumor cell-adipocyte gap junctions activate lipolysis and are essential for breast tumorigenesis. bioRxiv. https://doi.org/10.1101/277939
Winkler, J., Tan, W., Diadhiou, C. M., McGinnis, C. S., Abbasi, A., Hasnain, S., Durney, S., Atamaniuc, E., Superville, D., Awni, L., Lee, J. M., Hinrichs, J. H., Hein, M. Y., Borja, M. J. B., Detweiler, A. M., Liu, S., Nanjaraj, A., Sitarama, V., Rugo, H. S., . . . Werb, Z. (2022). Dissecting the contributions of tumor heterogeneity on metastasis at single-cell resolution. bioRxiv. https://doi.org/10.1101/2022.08.04.502697
Find out more information on Professor Goga’s research and recent
publications:
https://www.oncogenes.net/
Twitter @goga_lab
We welcome you to this exciting seminar!
Host: Juha Klefström
Student host: July Aung
CancerBio Summer School Organizing
Committee
Juha Klefström,
July Aung, Ylva von Wright, Kim Le, Victor Arias, Leticia Castillon,
Kerttu Kalander, Tatiana Kudling, James Clubb
HiLIFE Seminars Coordinating Team
Leonardo
Almeida-Souza, Jaan-Olle Andressoo, Anna Vähärautio, Anu Luoto